Drug
Glutamate decarboxylase 2 clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
Diamyd Therapeutics AB (4) · Norwegian University of Science and Technology (1) · Diamyd Medical AB (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
Often tested with
Tested in the same studies.
Retogatein (7) · Vitamin D (1) · Insulin (1) · Lansoprazole (1) · Sitagliptin (1)
Studies
Open first, then newest update. How each study uses glutamate decarboxylase 2 is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 DiabetesTerminatedPhase 3Diamyd Medical ABNCT05018585Written as Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
- Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of DiabetesCompletedPhase 2Norwegian University of Science and TechnologyNCT04262479Written as recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel
- Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 DiabetesTerminatedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00837759Written as GAD65 (Diamyd)
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENTTerminatedPhase 3Diamyd Therapeutics ABNCT00751842Written as rhGAD65
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)TerminatedPhase 3Diamyd Therapeutics ABNCT00723411Written as rhGAD65
- Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)CompletedPhase 2Diamyd Therapeutics ABNCT00456027Written as rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 DiabetesCompletedPhase 2Diamyd Therapeutics ABNCT00435981Written as rhGAD65 formulated in Alhydrogel® (Diamyd®)